Olaparib CAS 763113-22-0: Uses, Properties and API Buying Guide
Olaparib is a small-molecule PARP inhibitor with the chemical name associated with CAS No. 763113-22-0. For pharmaceutical manufacturers, research organizations, and raw material buyers, Olaparib is more than a pharmaceutical compound—it is a material that must be evaluated for identity, purity, specification, analytical data, and supply consistency.
This guide explains the key properties and applications of Olaparib, its mechanism of action, common pharmaceutical considerations, and the main points buyers should check when sourcing Olaparib API or pharmaceutical raw material.
If you are evaluating an Olaparib supplier, the most important information includes CAS number, molecular formula, specification, assay, impurity profile, batch-specific COA, SDS, packaging, lead time, and quality documentation.
What Is Olaparib CAS 763113-22-0?
laparib is a small-molecule poly(ADP-ribose) polymerase, or PARP, prevention. PubChem notes Olaparib under CAS No. 763113-22-0, with molecular formula C24H23FN4O3 and molecular weight 434.5 g/mol. It is additionally known by the advancement codes AZD2281 and KU-0059436.
Olaparib jobs by preventing PARP enzymes associated with DNA repair. Cancer cells that currently have problems in other DNA-repair paths, such as specific BRCA1/BRCA2 mutations, may be more depending on PARP-mediated repair. Blocking PARP can therefore increase DNA damage in vulnerable cancer cells and contribute to cell death.
From a pharmaceutical production viewpoint, the exact chemical identification is critical. Purchasers need to validate the CAS number, specification, assay, contamination restrictions, and analytical documentation prior to buying commercial quantities.
Olaparib Product Specifications at a Glance
| Property | Information |
|---|---|
| Product Name | Olaparib |
| CAS No. | 763113-22-0 |
| Molecular Formula | C24H23FN4O3 |
| Molecular Weight | 434.5 g/mol |
| Synonyms | AZD2281, KU-0059436 |
| Chemical Class | PARP inhibitor |
| Typical Form | Solid pharmaceutical raw material |
| Main Use | Pharmaceutical manufacturing and research |
| Typical Documents | COA, SDS/MSDS, TDS |
What Is Olaparib Utilized For?
Olaparib is mainly used in pharmaceutical applications related to PARP inhibition. Its uses can be viewed from both a clinical and pharmaceutical perspective, making it relevant to healthcare applications as well as pharmaceutical research and API sourcing.
1. Cancer Treatment Applications
Olaparib is used in specific cancer treatment settings where PARP inhibition may provide a therapeutic benefit. It has been associated with the treatment of certain ovarian, breast, pancreatic, and prostate cancers, depending on the patient’s disease characteristics and the applicable regulatory approval.
The use of Olaparib is not the same for every patient or cancer type. Approved indications, treatment combinations, and eligibility requirements can vary by country and may change as new clinical evidence becomes available. For this reason, current product labeling and local regulatory information should be consulted for medical use.
2. PARP Inhibitor Applications
Olaparib belongs to the PARP inhibitor class. PARP proteins play an important role in cellular DNA damage repair, and inhibiting these proteins can affect the ability of certain cells to repair DNA damage.
This mechanism has made Olaparib an important compound in oncology research. Scientists and pharmaceutical developers study its interaction with DNA repair pathways to better understand targeted cancer treatment and the potential role of PARP inhibition in different disease settings.
3. Pharmaceutical Research and Development
Beyond its approved medical applications, Olaparib is relevant to pharmaceutical research and development. Research organizations may use Olaparib-related materials when studying PARP inhibition, drug formulation, analytical methods, and other stages of pharmaceutical development.
For development projects, buyers may need to evaluate the identity, purity, analytical profile, and consistency of an Olaparib pharmaceutical raw material. Supporting documents such as a Certificate of Analysis (COA), Safety Data Sheet (SDS), and product specification can help technical and purchasing teams assess the material.
4. Olaparib API and Pharmaceutical Manufacturing
Olaparib is also relevant to pharmaceutical manufacturing as an active pharmaceutical ingredient (API). Pharmaceutical buyers sourcing Olaparib API generally need to consider more than the product name and price.
Exactly How Does Olaparib Work?
PARP proteins aid cells respond to and repair specific types of DNA damage. Olaparib inhibits PARP activity and influences the fixing of damaged DNA.
The device becomes particularly vital in tumor cells with specific issues in homologous recombination repair. When 2 DNA-repair paths suffer at the same time, the resulting damages can end up being tough for the cancer cells cell to survive.
This concept is typically referred to as artificial lethality. It is among the crucial scientific concepts behind PARP inhibitor treatment.
For pharmaceutical specialists, this mechanism additionally clarifies why olaparib high quality and identification issue. A specified energetic pharmaceutical component must satisfy the agreed chemical and analytical requirements prior to it can be considered suitable for downstream manufacturing.
Just how Should Olaparib Be Kept?
Olaparib must be saved according to the manufacturer’s existing specification and SDS. For pharmaceutical basic materials, buyers must focus on packaging integrity, moisture direct exposure, temperature control, and contamination danger.
Rather than relying on a common storage statement duplicated from an additional web site, customers must request the distributor’s real SDS and storage space recommendation for the supplied grade.
This is specifically vital when material will certainly be kept in inventory for months prior to production.
Olaparib Dosage and Management
Olaparib application ought to not be dealt with as a solitary universal number, due to the fact that the ideal dose depends on the indicator, formulation, patient aspects, concomitant medicines, and tolerability.
EMA states that Lynparza is supplied as tablets taken twice daily, while the dose depends on the disease being treated. Therapy might be disturbed or the dose decreased when specific unfavorable effects occur.
The FDA suggesting information supplies indication-specific dosing instructions and likewise includes dose-modification suggestions for damaging reactions and certain medication interactions.
This difference is essential due to the fact that olaparib has existed in different dosage types traditionally. Clients must comply with the instructions for the specific formulation prescribed to them and should not change dose, frequency, or solution without expert advice.
For an internet site focused on pharmaceutical customers, it is better to define the accepted dosing structure as opposed to supply a generic “one-size-fits-all” dosage suggestion.
Olaparib Drug Interactions
Olaparib might connect with certain medications and foods, primarily through the CYP3A enzyme path.
☑️CYP3A inhibitors, such as itraconazole, clarithromycin, erythromycin, diltiazem, and fluconazole, may increase olaparib degrees and the danger of negative effects.
☑️CYP3A inducers, consisting of rifampicin, phenytoin, carbamazepine, and phenobarbital, might minimize olaparib levels and potentially lower its effectiveness.
☑️Combining olaparib with various other myelosuppressive medications might enhance the threat of blood-related negative effects.
☑️Olaparib may additionally influence some medicines, including rosuvastatin, metformin, valsartan, and repaglinide.
☑️Some hormone contraceptives may be less effective when utilized with olaparib.
Throughout treatment, patients should usually avoid grapefruit, grapefruit juice, and Seville oranges, which might enhance olaparib direct exposure.
Olaparib Side Effects and Safety Risks
Like other prescription medicines, olaparib can cause side effects. The type and severity can vary between patients and treatment settings. Commonly reported adverse reactions include:
Common Side Effects
- Nausea– one of the most commonly reported gastrointestinal effects.
- Fatigue or asthenia– patients may experience tiredness, weakness, or reduced energy.
- Anemia– reduced red blood cell or hemoglobin levels can occur during treatment.
- Vomiting– gastrointestinal symptoms may occur, particularly during the early stages of treatment.
- Diarrhea– changes in bowel habits can occur and may require medical management if persistent.
- Decreased appetite– some patients may experience reduced appetite during treatment.
- Headache– headache has been reported among commonly observed adverse reactions.
- Taste disturbance (dysgeusia)– some patients may notice changes in taste.
- Neutropenia– a decrease in neutrophil levels may occur.
- Leukopenia– reduced white blood cell counts have also been reported.
Olaparib API Buying Guide
Buying Olaparib API requires a different approach from purchasing a standard industrial chemical. Pharmaceutical buyers need to consider product quality, documentation, supply stability, and the intended stage of their project.
What Should Buyers Check Before Ordering Olaparib?
Before requesting a quotation or placing an order, buyers can ask the supplier for the following information:
1. Product identification
Confirm the product name, CAS No. 763113-22-9, molecular formula, molecular weight, and other relevant identification information.
2. Product specification
Review the available specification, including assay, appearance, impurities, moisture or other applicable quality parameters.
3. COA
Ask for a batch-specific Certificate of Analysis (COA) when available. The COA allows buyers to review the analytical results of a specific batch rather than relying only on a general product description.
4. SDS and technical documents
An SDS provides important information for storage, handling, transportation, and workplace safety. Depending on the project, buyers may also request technical documentation or other quality records.
5. Sample availability
For new supplier evaluation, a sample can help the buyer conduct internal testing before moving to a larger purchase.
6. Packaging
Packaging should be suitable for the product and the planned transportation conditions. Buyers should confirm the available package size before ordering.
7. Supply capability
For ongoing projects, supply consistency can be just as important as the initial price. Ask about production or sourcing capability, normal lead time, available package sizes, and the supplier’s ability to support repeat orders.
8. Quality consistency
If Olaparib will be used in a long-term project, buyers should consider whether the supplier can maintain consistent specifications between batches.
Faq
Yes. Olaparib is the active pharmaceutical ingredient in Lynparza and belongs to the PARP inhibitor class.
Olaparib is used in several approved oncology settings, including certain ovarian, breast, pancreatic, prostate, and endometrial cancers. The exact approved indication depends on factors such as tumor type, BRCA/HRD status, previous treatment, and regulatory jurisdiction.
Common adverse reactions include nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, and taste disturbance. Blood-count abnormalities can also occur. Serious risks require medical monitoring.
Buyers should check the CAS number, product specification, assay, impurity profile, batch-specific COA, SDS, TDS, sample availability, production capability, packaging, lead time, and batch consistency. Price should be considered together with quality and supply reliability.
Shandong Zhishang Bio Co., Ltd
Zhishang Bio, a subsidiary of Zhishang Chemical Co., Ltd., was established in 2016 and is a new type of chemical enterprise that integrates research and development, production, and sales. Zhishang Bio always adheres to the concept of “integrity management, strict quality control, customer first”.
Through continuous efforts, significant breakthroughs have been made in industries such as pharmaceutical intermediates, pesticide intermediates, food additives, and cosmetic raw materials. The domestic trade team sells well throughout the country, while the foreign trade team is exported to more than 30 countries and regions including the United States, Russia, Spain, Brazil, and enjoys a global reputation.
Invited to participate in this exhibition, Zhishang Bio will comprehensively showcase the company’s strength and achievements in the research and development, production, and quality control of pharmaceutical and pesticide intermediates! At that time, our company will set up an CPHI exhibition at booth E12D29 at the venue, and we will take you to further understand our company’s advantageous products in detail!
You may also want to read
